INZY vs. AXSM

In the year-to-date period, INZY achieves a 42.60% return, which is significantly higher than AXSM's 28.06% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Inozyme Pharma, Inc. (INZY) and Axsome Therapeutics, Inc. (AXSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current INZY Sharpe Ratio is -0.08, which is lower than the AXSM Sharpe Ratio of 0.87. The chart below compares the historical Sharpe Ratios of INZY and AXSM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither INZY nor AXSM has paid dividends to shareholders.

The maximum INZY drawdown since its inception was -97.28%, which is greater than AXSM's maximum drawdown of -86.65%. Use the drawdown chart below to compare losses from any high point for INZY and AXSM. For additional features, visit the drawdowns tool.

Inozyme Pharma, Inc. (INZY) has a higher volatility of 110.74% compared to Axsome Therapeutics, Inc. (AXSM) at 9.43%. This indicates that INZY's price experiences larger fluctuations and is considered to be riskier than AXSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Inozyme Pharma, Inc. and Axsome Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.